Date: 2015-08-23
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: BMS (USA - NY)
Product: BMS-986165
Action mechanism:
Disease: lupus, psoriasis
Therapeutic area: Autoimmune diseases - Dermatological diseases
Country:
Trial
details: This randomized, double-blind, placebo-controlled, single and multiple ascending dose study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-986165 in healthy subjects and to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical efficacy of BMS-986165 in subjects with moderate to severe psoriasis. (NCT02534636)
Latest
news: The purpose of this study is to establish if BMS-986165 is safe and effective at treating autoimmune diseases such as psoriasis. This study will be run in 5 Parts. Part A will investigate single oral doses of drug. Part B will investigate giving the drug daily for 14 days. Part C will investigate daily doses for 14 days in healthy volunteers with Japanese decent. Part D will investigate whether food, stomach acidity or giving the drug in a capsule makes a difference to the safety and potential use of this drug and Part E will investigate the ability of this drug to treat psoriasis.
